Who needs Game of Thrones when you can summarize a paper by "(CARs) promote antigen loss in tumour cells by trogocytosis, which results in T cell fratricide killing and exhaustion but can be counteracted by cooperative killing and combinatorial targeting."

Online @nature: CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape nature.com/articles/s4158…

Mind blowing paper by Sadalain lab: trogocytosis and cooperative killing regulate tumour antigen escape. What an interesting mechanism of immune escape! ⁦The Society of MSKCC⁩ ⁦@nature⁩ ⁦⁦ nature.com/articles/s4158…

Loss of antigens, and T cell dysfunction are hurdles for successful #CARTcell therapies. A new study published by authors from @sloan_kettering in @nature show that "CARs provoke reversible antigen loss through #trogocytosis". #Immunotherapy #cancer nature.com/articles/s4158…

ICYMI, @sloan_kettering scientists have identified new structures that play a critical role in one of the most protective kinds of #intercellular communication – the “lethal” interaction between a cytotoxic #Tcell and its targets: fcld.ly/qdfbmdd

Brilliant...

Don't bite off more than you can chew! CD19 #CARTcells acquire CD19 from #cancer cells by #trogocytosis, helping #tumor #escape by #antigenloss and by getting killed by other CD19 CAR T cells in #fratricide! #immunologymatters @sloan_kettering @nature

What is the difference between 28z and BBz CAR-T ? Toxicity , persistence, effector function . Beautiful talk by Michel Sadelain @sloan_kettering #AACR19

CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape go.nature.com/2FLNOz2 @sloan_kettering

The new smart cars at #AACR19 : Sadelain, Lim highlight current thinking of improving CAR-T #immunotherapy, by targeting with 2 distinct CAR (nature.com/articles/s4158…) or building dual or triple antigen sensors (with this strat : sciencedirect.com/science/articl… )

Online today: long-term data from the MSK phase I experience with 19-28z CAR T-cells for R/R CLL. Severe CRS/neurotox rare. Subgroup of patients achieves durable CR. Ibrutinib may modulate ex vivo expansion and T-cell phenotypes. insight.jci.org/articles/view/… #leusm #lymsm #cart

2019-31852 Senior Research Technician | Memorial Sloan Kettering Cancer Center Careers careers.mskcc.org/jobs/job-detai…

🚨 Our Dr. Michel Sadelain will deliver the George Stamatoyannopoulos Memorial Lecture tomorrow at #ASGCT19. The lecture will focus on CAR T cell engineering – the makings of a living drug. For more of Dr. Sadelain's award-winning research, click here: bit.ly/2V4d1hf

Congratulations to Michel Sadelain for receiving the 2019 Gabbay Award, jointly with Dario Campana, in recognition of his pioneering work in the development of CAR T-cell therapy for cancer. brandeis.edu/rosenstiel/gab…

In the April issue of Cancer Discovery - a new review by Hamieh Mohamad Jorge Mansilla-Soto Isabelle Rivière & @Michel_Sadelain Memorial Sloan Kettering Cancer Center: Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating aacrjournals.org/cancerdiscover… #immunotherapy

✨ONLINE NOW Nature Cancer “Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies” #CARTcells nature.com/articles/s4301…

Our new paper describing a novel synthetic co-stimulatory molecule designed to boost anti-tumor responses is out in Nature Cancer . nature.com/articles/s4301…

A daring cancer therapy that few doctors believed would work has sent some cancer patients into complete remission. nyti.ms/2anELTY